1. Limitations of fibrosis grade as diagnostic criteria for post polycythemia vera and essential thrombocytosis myelofibrosis. Issue 7 (July 2015) Authors: Gowin, K.; Verstovsek, S.; Daver, N.; Pemmaraju, N.; Valdez, R.; Kosiorek, H.; Dueck, A.; Mesa, R. Journal: Leukemia research Issue: Volume 39:Issue 7(2015:Jul.) Page Start: 684 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Multicenter phase 2 study of combination therapy with ruxolitinib and danazol in patients with myelofibrosis. (September 2017) Authors: Gowin, K.; Kosiorek, H.; Dueck, A.; Mascarenhas, J.; Hoffman, R.; Reeder, C.; Camoriano, J.; Tibes, R.; Gano, K.; Palmer, J.; Mesa, R. Journal: Leukemia research Issue: Volume 60(2017:Sep.) Page Start: 31 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P1030: MANIFEST-2, A GLOBAL, PHASE 3, RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROL STUDY OF PELABRESIB (CPI-0610) AND RUXOLITINIB VS PLACEBO AND RUXOLITINIB IN JAK INHIBITOR-NAÏVE MYELOFIBROSIS PATIENTS. (23rd June 2022) Authors: Harrison, C.; Rampal, R. K.; Gupta, V.; Verstovsek, S.; Talpaz, M.; Kiladjian, J.-J.; Mesa, R.; Kuykendall, A.; Vannucchi, A.; Palandri, F.; Grosicki, S.; Devos, T.; Jourdan, E.; Wondergem, M. J.; Al-Ali, H. K.; Buxhofer-Ausch, V.; Alvarez-Larrán, A.; Akhani, S.; Muñoz-Carerras, R.; Sheykin, Y. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 920 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. P1050: THROMBOCYTOPENIC MYELOFIBROSIS (MF) PATIENTS PREVIOUSLY TREATED WITH A JAK INHIBITOR IN A PHASE 3 RANDOMIZED STUDY OF MOMELOTINIB (MMB) VERSUS DANAZOL (DAN) [MOMENTUM]. (23rd June 2022) Authors: Vannucchi, A.; Mesa, R.; Gerds, A.; Al-Ali, H. K.; Lavie, D.; Kuykendall, A.; Grosicki, S.; Iurlo, A.; Goh, Y. T.; Lazaroiu, M.; Egyed, M.; Fox, M. L.; McLornan, D.; Perkins, A.; Yoon, S.-S.; Gupta, V.; Kiladjian, J.-J.; Donahue, R.; Kawashima, J.; Verstovsek, S. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 940 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. P1051: A PHASE 2 STUDY OF IMG-7289 (BOMEDEMSTAT) IN PATIENTS WITH ADVANCED MYELOFIBROSIS. (23rd June 2022) Authors: Gill, H.; Yacoub, A.; Pettit, K.; Bradley, T.; Gerds, A.; Tatarczuch, M.; Shortt, J.; Curtin, N.; Rossetti, J.; Burbury, K.; Mead, A.; Göthert, J.; Koschmieder, S.; Jones, A.; Peppe, J.; Dias, J.; Natsoulis, G.; McClure, T.; Kleppe, M.; Hong, W.-J. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 941 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. P1062: A REAL-WORLD EVALUATION OF THE ASSOCIATION BETWEEN ELEVATED BLOOD COUNTS AND THROMBOTIC EVENTS IN POLYCYTHEMIA VERA: AN ANALYSIS OF DATA FROM THE REVEAL STUDY. (23rd June 2022) Authors: Gerds, A. T.; Mesa, R.; Burke, J. M.; Grunwald, M. R.; Scherber, R.; Yu, J.; Hamer-Maansson, J.; Oh, S. T. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 952 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. P1068: RISK-ADJUSTED SAFETY ANALYSIS OF PACRITINIB IN PATIENTS WITH MYELOFIBROSIS. (23rd June 2022) Authors: Vannucchi, A.; Pemmaraju, N.; Scott, B.; Savona, M.; Oh, S.; Palandri, F.; Al-Ali, H. K.; Sobas, M.; McMullin, M. F.; Gupta, V.; Yacoub, A.; Mesa, R.; Buckley, S.; Roman-Torres, K.; Verstovsek, S.; Harrison, C. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 958 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. P1069: RETROSPECTIVE COMPARISON OF PATIENT OUTCOMES ON PACRITINIB VERSUS RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS AND THROMBOCYTOPENIA. (23rd June 2022) Authors: Harrison, C.; Bose, P.; Mesa, R.; Gerds, A.; Oh, S.; Kiladjian, J.-J.; García-Gutierrez, V.; Vannucchi, A.; Scheid, C.; Sobas, M.; Verstovsek, S.; Buckley, S.; Roman-Torres, K.; Mascarenhas, J. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 959 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Pegylated interferon alpha – 2a is clinically effective and tolerable in myeloproliferative neoplasm patients treated off clinical trial. (March 2017) Authors: Gowin, K.; Jain, T.; Kosiorek, H.; Tibes, R.; Camoriano, J.; Palmer, J.; Mesa, R. Journal: Leukemia research Issue: Volume 54(2017:Mar.) Page Start: 73 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. S195: MOMENTUM: PHASE 3 RANDOMIZED STUDY OF MOMELOTINIB (MMB) VERSUS DANAZOL (DAN) IN SYMPTOMATIC AND ANEMIC MYELOFIBROSIS (MF) PATIENTS PREVIOUSLY TREATED WITH A JAK INHIBITOR. (23rd June 2022) Authors: Verstovsek, S.; Vannucchi, A.; Gerds, A.; Al-Ali, H. K.; Lavie, D.; Kuykendall, A.; Grosicki, S.; Iurlo, A.; Goh, Y. T.; Lazaroiu, M.; Egyed, M.; Fox, M. L.; McLornan, D.; Perkins, A.; Yoon, S.-S.; Gupta, V.; Kiladjian, J.-J.; Donahue, R.; Kawashima, J.; Mesa, R. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 96 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗